Altre lingue Active Biotech AB

Azioni

ACTI

SE0001137985

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 17:29:47 31/05/2024			Variaz. 5gg	Var. 1 gen.
0,56 ^SEK	+4,09%		+14,52%	+22,67%

22/05	Active Biotech stipula un accordo di licenza esclusiva con l'Istituto Wistar di Anatomia e Biologia	CI
08/05	Active Biotech AB (publ) riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Active Biotech Enters into an Exclusive License Agreement with the Wistar Institute of Anatomy and Biology	22/05
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	03/04
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/02
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023	08/02
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024	22/12
Active Biotech Raises SEK44 Million via Rights Offering	06/12
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops	06/12
Active Biotech AB Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee	01/12
Rights Issue: 3 new shares @ 0.45 SEK for 7 existing shares	15/11	FA
Active Biotech AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Active Biotech AB Announces Two Abstracts with Preclinical Data for Tasquinimod in Myelofibrosis and Myelodysplastic Syndrome Have Been Accepted for Presentation At Ash 2023	02/11
Active Biotech AB Announces Successful Completion of Dose Escalation of Tasquinimod	11/09/23
Active Biotech AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23
Active Biotech Signs Collaboration Deal For Blood Cancer Drug Clinical Trial	31/07/23
Active Biotech AB Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis	31/07/23
Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma	26/05/23
Active Biotech AB Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23
Active Biotech AB Auditor Raises 'Going Concern' Doubt	26/04/23
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	09/02/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Active Biotech AB

Azioni

ACTI

SE0001137985

Altre lingue

Filtri